30 closest matches · ranked by relevance
HPV Vaccination Decision Quality
Primary: Percent of Participants - Who Agreed They Felt Sure About the Best Choice Regarding the HPV Vaccine at Post-intervention — 94; 95; 89 Percent of participants — p=0.069
Human Papillomavirus · Prevention
Primary: Mother's Intention to Vaccinate Daughter Against HPV — 1.53; 1.29 units on a scale
Papillomavirus Vaccines
Primary: Human Papillomavirus or HPV-vaccine-dose Receipt — 782; 578; 408; 1056 Participants
Vaccination
Primary: GARDASIL Vaccination Uptake and Compliance With Second and Third Doses — 12; 12; 8; 3 participants — p=>.05
Human Papillomavirus Vaccines · Adolescent Health Services
Primary: HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months — 3189; 3833; 4260 Participants
Human Papilloma Virus Vaccines · Attitude to Health
Primary: Intention to Vaccinate Against HPV in the Next 12 Months — 3.49; 3.87; 4.16 score on a scale — p=<.02
Human Papilloma Virus Infection Type 11 · Human Papilloma Virus Infection Type 16 · Human Papilloma Virus Infection Type 18
Primary: First Dose HPV Vaccine Uptake — 118; 63; 117 Participants
HPV-Related Malignancy
Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants
Vaccine · Human Papilloma Virus
Primary: Change in Attitudes About HPV Vaccine — .16; -.08 units on a scale — p=.003
Human Papilloma Virus
Primary: Overall HPV Vaccine Completion Rates — 1961; 1083 Participants
Immunization · Vaccination
Primary: Change in the Rate of Missed Vaccination Opportunities Among All Clinicians — 37063; 40764; 14932; 18343 Eligible visits (due for vaccine)
Gardasil Vaccine · Stem Cell Transplant · Immunogenicity
Primary: Percentage of Subjects Who Developed Antibody Response to the Vaccine. — 18; 20; 20 Participants
Human Papillomavirus Vaccines
Primary: Initiation of the HPV Vaccine 2-dose Series. — 1723; 1219 Participants
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
GARDASIL Vaccination
Primary: On-time Completion of the Human Papillomavirus Vaccine Series — 36; 31 participants
Human Papillomavirus
Primary: Number of Participants Who Completed HPV Vaccine Series — 364; 344 Participants
HPV Vaccine · HPV
Primary: Part 1: HPV Vaccine Knowledge (Aim 1) — 10.10; 3.19 score on a scale
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
HPV Vaccination Status
Primary: Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period — 8; 9; 3 participants — p=.36
Infections, Papillomavirus
Primary: Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)…
Cervical Cancer
Primary: The Receipt of the First HPV Vaccination — 51; 56 percentage of participants
Human Papillomavirus Infection
Primary: Antibody Response to HPV Vaccine for HPV 6,11,16,18. — 1086.49; 1054.13; 745.06; 776.84 Milli Merck Units — p=>0.20
Human Papillomavirus
Primary: Number of Students Who Initiated the HPV Vaccine Series as a Result of the School-based Program — 315 participants
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…
Cancer Survivor · Prevention of Human Papillomavirus Infection
Primary: Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey]) — 179 Participants
Infections, Papillomavirus
Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants
HPV Vaccination
Primary: Count of Eligible Patients Agreeing to Receive a Dose of Vaccine — 686; 101 participants
Vaccine Hesitancy
Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…
Infections, Papillomavirus
Primary: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection — 190; 181 Participants
Papillomavirus Infections
Primary: Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7 — 96.97; 99.05; 99.05; 99.05 percentage of participants